Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Pharmaceutics and Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran; Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Int J Pharm. 2024 Sep 5;662:124518. doi: 10.1016/j.ijpharm.2024.124518. Epub 2024 Jul 27.
Cerasomes are a modified form of liposomes containing both inorganic and organic parts and due to their strong polyorganosiloxane surface have remarkably high morphological stability and provide easier functionalization compared with conventional liposomes. To investigate the potential of these nanocarriers for oral delivery, bile salt integrated cerasomes (named bilocerasomes) encapsulating idarubicin hydrochloride (IDA) were prepared and characterized. The optimum formulation showed excellent stability in the simulated gastrointestinal fluids as well as under storage conditions. The oral pharmacokinetics of the IDA solution, empty nanocarrier + drug solution, and IDA-loaded bilocerasome were evaluated. The nanoformulation significantly increased the area under the drug concentration-time curve and the mean residence time (∼14.3- and 9-fold, respectively). The results obtained from cell uptake and chylomicron flow blocking approach revealed that bilocerasomes are absorbed into the intestinal cells via a clathrin/caveolin-independent endocytosis pathway and transported to the systemic circulation extensively via the intestinal lymphatic vessels. Considering the high stability of the prepared bilocerasome, noticeable participation of lymphatic transport in its systemic absorption and marked enhancement in the oral absorption of IDA, bilocerasomes can be introduced as a capable carrier for improving the oral bioavailability of drugs, particularly those that hepatic first-pass metabolism seriously limits their oral absorption.
类脂体是一种改良的脂质体,含有无机和有机部分,由于其强聚有机硅氧烷表面,具有非常高的形态稳定性,并提供更容易的功能化与传统的脂质体相比。为了研究这些纳米载体用于口服给药的潜力,制备并表征了含有盐酸伊达比星(IDA)的胆汁盐整合类脂体(命名为bilocerasomes)。最佳配方在模拟胃肠道液和储存条件下均表现出优异的稳定性。评价了伊达比星溶液、空纳米载体+药物溶液和负载伊达比星的bilocerasome的口服药代动力学。纳米制剂显著增加了药物浓度-时间曲线下面积和平均滞留时间(分别约为 14.3 倍和 9 倍)。从细胞摄取和乳糜微粒流动阻断方法获得的结果表明,bilocerasomes 通过网格蛋白/小窝蛋白非依赖性内吞作用途径被吸收到肠细胞中,并通过肠淋巴血管广泛运输到全身循环。考虑到制备的bilocerasome 的高稳定性、淋巴转运在其全身吸收中的显著参与以及伊达比星口服吸收的显著增强,bilocerasome 可以作为一种有效的载体,用于提高药物的口服生物利用度,特别是那些肝脏首过代谢严重限制其口服吸收的药物。